2003
DOI: 10.1002/bip.10520
|View full text |Cite
|
Sign up to set email alerts
|

New approaches to targeting RNA with oligonucleotides: Inhibition of group I intron self‐splicing

Abstract: RNA is one class of relatively unexplored drug targets. Since RNAs play a myriad of essential roles, it is likely that new drugs can be developed that target RNA. There are several factors that make targeting RNA particularly attractive. First, the amount of information about the roles of RNA in essential biological processes is currently being expanded. Second, sequence information about targetable RNA is pouring out of genome sequencing efforts at unprecedented levels. Third, designing and screening potentia… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
16
0

Year Published

2005
2005
2011
2011

Publication Types

Select...
9
1

Relationship

3
7

Authors

Journals

citations
Cited by 19 publications
(16 citation statements)
references
References 98 publications
(108 reference statements)
0
16
0
Order By: Relevance
“…4043 Much less effort, however, has been applied to development and testing of force fields for RNA. The emerging recognition that RNA has many different cellular functions 1−6 and that many RNAs are potential therapeutic targets 27,4447 increases the importance of force fields for RNA.…”
Section: Discussionmentioning
confidence: 99%
“…4043 Much less effort, however, has been applied to development and testing of force fields for RNA. The emerging recognition that RNA has many different cellular functions 1−6 and that many RNAs are potential therapeutic targets 27,4447 increases the importance of force fields for RNA.…”
Section: Discussionmentioning
confidence: 99%
“…RNA structural motifs may be targeted with oligonucleotides (Childs et al 2002(Childs et al , 2003Disney et al 2004) or small molecules (Mei et al 1998;Sucheck and Wong 2000;Wilson and Li 2000;Gallego and Varani 2001;Childs-Disney et al 2007;Disney et al 2008; Lee et al 2009;Pushechnikov et al 2009) to disrupt viral function.…”
Section: Introductionmentioning
confidence: 99%
“…Group I and group II introns have also been engineered as tools in biotechnology and molecular medicine, e.g. for targeted gene knock-out/knock-down, gene delivery or gene therapy systems (4,9,22–25), and may as well be the targets for therapeutics (26). …”
Section: Introductionmentioning
confidence: 99%